Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3382 |
Name | liposarcoma |
Definition | A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer lipomatous cancer liposarcoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Recruiting | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02343172 | Phase Ib/II | HDM201 + Ribociclib | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | Completed | CAN | 5 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Active, not recruiting | USA | 0 |
NCT02606461 | Phase II | Selinexor | KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL) | Active, not recruiting | USA | CAN | 8 |
NCT02846987 | Phase II | Abemaciclib | Study of Abemaciclib in Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT02923778 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Recruiting | USA | CAN | 0 |
NCT02978859 | Phase II | MGCD516 | MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03074318 | Phase Ib/II | Avelumab + Trabectedin | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03114527 | Phase II | Everolimus + Ribociclib | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Recruiting | USA | 0 |
NCT03190174 | Phase Ib/II | Nab-Rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Recruiting | USA | 0 |
NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Recruiting | USA | 3 |
NCT03719430 | Phase II | APX005M + Doxorubicin + Olaratumab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Recruiting | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT03964233 | Phase I | BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | 1 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Recruiting | USA | 0 |
NCT04242238 | Phase I | Avelumab + DCC-3014 | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) | Recruiting | USA | 0 |